Yellow fever vaccine - GE Healthcare

Drug Profile

Yellow fever vaccine - GE Healthcare

Alternative Names: XRX-001; XRX-001 inactivated yellow fever vaccine - GE Healthcare; XRX-001 yellow fever 17D, inactivated vaccine, alum adsorbed - GE Healthcare

Latest Information Update: 11 Oct 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xcellerex
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Yellow fever

Highest Development Phases

  • No development reported Yellow fever

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Yellow-fever(Prevention) in USA (Parenteral, Injection)
  • 07 Apr 2011 Yellow fever vaccine - Xcellerex is available for licensing as of 07 Apr 2011.
  • 07 Apr 2011 Immunogenicity and adverse events data from a phase I trial in Healthy volunteers released by Xcellerex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top